Clinical Trial Update: EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update examining EF5 as a biomarker to assess tumor response to anticancer therapy in patients with stage I-III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EF5

Snippet

Sponsor: Duke University | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED